Fortress Biotech, Inc. (FBIO) and its majority-owned subsidiary, Cyprium Therapeutics, Inc., announced that Cyprium has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205 million, subject to customary closing conditions.
The PRV was issued following the U.S. FDA approval of ZUCUBO (copper histidinate, formerly known as CUTX-101) on January 12, 2026, for the treatment of Menkes disease in pediatric patients.
Cyprium had previously transferred development and commercialization rights for ZUCUBO to Sentynl Therapeutics in December 2023, while retaining eligibility for tiered royalties on net sales and up to $129 million in milestone payments. Under the agreement, Cyprium will also remit 20% of PRV sale proceeds to the Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Lindsay A.Rosenwald, M.D., Fortress' Chairman, President and CEO, highlighted the transaction as part of Fortress' ongoing execution of value-generating corporate strategies, noting three FDA approvals in the past 15 months and the recent sale of Checkpoint Therapeutics to Sun Pharma. Lung S. Yam, Cyprium's President and CEO, emphasized the approval of ZUCUBO as a milestone for Menkes disease patients and reaffirmed Cyprium's commitment to advancing its AAV-ATP7A gene therapy program.
FBIO has traded between $1.33 and $4.53 over the past year. The stock is currently trading at $4.03, up 20%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.